 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Lacnotuzumab combined with gemcitabine-carboplatin in the treatment of advanced triple-negative breast cancer

Clin Cancer Res: Lacnotuzumab combined with gemcitabine-carboplatin in the treatment of advanced triple-negative breast cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

formaldehyde phase 2

side effects anoro

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Triple negative breast cancer (TNBC) accounts for approximately 15%-20% of all breast cancers

Lacnotuzumab (MCS110) is a neutralizing human IgG1 κ monoclonal antibody that can bind to CSF1 and block CSF1-mediated receptor activation

This study is a phase II clinical trial designed to evaluate the efficacy of Lacnotuzumab in the combination of gemcitabine and carboplatin for patients with advanced TNBC

Recruiting advanced TNBC female patients with high levels of tumor-related macrophages who are not suitable for surgery or radiotherapy for curative treatment, are treated with gemcitabine + carboplatin with or without Lacnotuzumab until intolerable toxicity, disease progression, doctors Or the patient decides to stop treatment

Progression-free survival of the two treatment groups

A total of 49 patients were recruited, of which 34 received Lacnotuzumab + gemcitabine + carboplatin treatment, and 15 patients received gemcitabine + carboplatin treatment

The best treatment response of the two treatment groups

The median progression-free survival in the combination group and gemcitabine+carboplatin group were 5.

The median progression-free survival of the combination group and gemcitabine+carboplatin group were 5.

Lacnotuzumab + gemcitabine + carboplatin showed comparable antitumor activity to gemcitabine + carboplatin alone in advanced TNBC , but the tolerance was slightly poor.

Original source:

Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.